Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy
Open Access
- 27 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Glioblastoma is the most common and lethal brain cancer globally. Clinically, this cancer has heterogenous molecular and clinical characteristics. Studies have shown that UBE2S is highly expressed in many cancers. But its expression profile in glioma, and the correlation with clinical outcomes is unknown. RNA sequencing data of glioma samples was downloaded from the Chinese Glioma Genome Atlas and The Cancer Genome Atlas. A total of 114 cases of glioma tissue samples (WHO grades II-IV) were used to conduct protein expression assays. The molecular and biological characteristics of UBE2S, and its prognostic value were analyzed. The results showed that high UBE2S expression was associated with a higher grade of glioma and PTEN mutations. In addition, UBE2S affected the degree of malignancy of glioma and the development of chemo-radiotherapy resistance. It was also found to be an independent predictor of worse survival of LGG patients. Furthermore, we identified five UBE2S ubiquitination sites and found that UBE2S was associated with Akt phosphorylation in malignant glioblastoma. The results also revealed that UBE2S expression was negatively correlated with 1p19q loss and IDH1 mutation; positively correlated with epidermal growth factor receptor amplification and PTEN mutation. This study demonstrates that UBE2S expression strongly correlates with glioma malignancy and resistance to chemo-radiotherapy. It is also a crucial biomarker of poor prognosis.Keywords
This publication has 29 references indexed in Scilit:
- Current Challenges and Opportunities in Treating GlioblastomaPharmacological Reviews, 2018
- A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancerBMC Cancer, 2018
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastomaAnnals of Oncology, 2017
- Current and Future Drug Treatments for GlioblastomasCurrent Medicinal Chemistry, 2016
- Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastomaBrain Tumor Pathology, 2015
- Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?2015
- The Effects of Prostaglandin Analogues on Intracellular Ca 2+ in Ciliary Arteries of Wild-Type and Prostanoid Receptor-Deficient MiceJournal of Ocular Pharmacology and Therapeutics, 2013
- The Ubiquitin-Conjugating Enzyme E2-EPF Is Overexpressed in Primary Breast Cancer and Modulates Sensitivity to Topoisomerase II InhibitionNeoplasia, 2007
- E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasisNature Medicine, 2006
- Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancerProceedings of the National Academy of Sciences, 2001